STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Molecular Biotechnological Research Original Research

Molecular Docking of Saraca asoca (Ashoka) Phytocompounds for Ovarian Cancer Therapy

  1. A. Anandha Keerthana Department of Bioinformatics, Bionome, Bengaluru

Abstract

Objective: One of the top five cancers that causes death in women is ovarian cancer, with increases awareness till date the rate of survival is unpredictable. Even though there are advance treatments introduced, chemotherapy is most suggested to the ovarian cancer patients but the rate of relapses increased and the tumors get resistant towards the drugs. This present study is to evaluate the interaction of phytocompounds from Saraca asoca an Indian medicinal plant with VEGF protein that is essential for metastasis of the tumor cells by docking studies.

Methods: The In-silico study involved retrieval of phytocompounds of Saraca asoca from IMPPAT database and analysed for the pharmacokinetic properties by ADME analysis. These phytocompounds are evaluated with the target 3V2A protein by PyRx and BIOVIA Discovery studio to deduct the binding affinity of the ligand and protein.

Result: Among the 11 phytocompounds after the ADME and docking results showed that (–)–epicatechin was ideal phytocompound for 3V2A protein associated with ovarian cancer.

Conclusion: (-)-epicatechin can be a promising alternative for ovarian cancer treatment further research to be done to analysis their effect.

Keywords

References (27)

  1. Book BU. Ovarian Cancers: Evolving Paradigms in Research and Care. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington DC: The National Academic press; 2016. 1–396.
  2. Knapp RC. Reflections on Ovarian Cancer: A 33-Year Experience. Gynecologic Oncology. 1994;54(2):124-129. doi:10.1006/gyno.1994.1180
  3. Shafabakhsh R, Asemi Z. Quercetin: a natural compound for ovarian cancer treatment. Journal of Ovarian Research. 2019;12(1). doi:10.1186/s13048-019-0530-4
  4. Mesiano S, Ferrara N, Jaffe RB. Role of Vascular Endothelial Growth Factor in Ovarian Cancer. The American Journal of Pathology. 1998;153(4):1249-1256. doi:10.1016/s0002-9440(10)65669-6
  5. Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer and Metastasis Reviews. 2011;31(1-2):143-162. doi:10.1007/s10555-011-9337-5
  6. Quental MV, Pereira MM, Silva FAE, Coutinho JAP, Freire MG. Aqueous Biphasic Systems Comprising Natural Organic Acid-Derived Ionic Liquids. Separations. 2022;9(2):46. doi:10.3390/separations9020046
  7. Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecologic Oncology. 2009;113(1):143-148. doi:10.1016/j.ygyno.2008.11.032
  8. Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Frontiers in Bioscience. 2006;11(1):11. doi:10.2741/1839
  9. Mukherjee S, Abdalla M, Yadav M, Madhavi M, Bhrdwaj A, Khandelwal R, et al. Structure-Based Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation of VEGF inhibitors for the clinical treatment of Ovarian Cancer. Journal of Molecular Modeling. 2022;28(4). doi:10.1007/s00894-022-05081-3
  10. Capozzi VA, Rosati A, Turco LC, Sozzi G, Riccò M, Chiofalo B, et al. Surgery vs. chemotherapy for ovarian cancer recurrence: what is the best treatment option. Gland Surgery. 2020;9(4):1112-1117. doi:10.21037/gs-20-326
  11. Anastasia P. Intraperitoneal chemotherapy for ovarian cancer. Oncol Nursing Forum. 2012;39(4):346.
  12. Wu J, Zhou T, Wang Y, Jiang Y, Wang Y. Mechanisms and Advances in Anti-Ovarian Cancer with Natural Plants Component. Molecules. 2021;26(19):5949. doi:10.3390/molecules26195949
  13. Dharshini AD, Elumalai P, Raghunandhakumar S, Lakshmi T, Roy A. Evaluation of Anti-Cancer Activity of Saraca asoca Flower Extract against Lung Cancer Cell Line. Journal of Pharmaceutical Research International. 2021:423-431. doi:10.9734/jpri/2021/v33i62a35617
  14. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Research. 2018;46(W1):W296-W303. doi:10.1093/nar/gky427
  15. Durán-Iturbide NA, Díaz-Eufracio BI, Medina-Franco JL. In Silico ADME/Tox Profiling of Natural Products: A Focus on BIOFACQUIM. ACS Omega. 2020;5(26):16076-16084. doi:10.1021/acsomega.0c01581
  16. Kim S, Bolton EE. PubChem: A Large‐Scale Public Chemical Database for Drug Discovery. Methods and Principles in Medicinal Chemistry. 2023:39-66. doi:10.1002/9783527830497.ch2
  17. Shakoor B, Yaqoob N, Shafiq N, Bin Jardan YA, Nafidi HA, Bourhia M. In Silico ADME/Tox Profiling of Mushroom Secondary Metabolites. ChemistrySelect. 2024;9(4). doi:10.1002/slct.202304312
  18. Asirvatham RD, Hwang DH, Prakash RLM, Kang C, Kim E. Pharmacoinformatic Investigation of Silymarin as a Potential Inhibitor against Nemopilema nomurai Jellyfish Metalloproteinase Toxin-like Protein. International Journal of Molecular Sciences. 2023;24(10):8972. doi:10.3390/ijms24108972
  19. Ferrari IV, Patrizio P. Development and Validation Molecular Docking Analysis of Human serum albumin (HSA). 2021. doi:10.1101/2021.07.09.451789
  20. Rais J. Phytochemicals in the treatment of ovarian cancer nbsp. Frontiers in Bioscience. 2017;9(1):67-75. doi:10.2741/e786
  21. Haque A, Baig GA, Alshawli AS, Sait KHW, Hafeez BB, Tripathi MK, et al. Interaction Analysis of MRP1 with Anticancer Drugs Used in Ovarian Cancer: In Silico Approach. Life. 2022;12(3):383. doi:10.3390/life12030383
  22. Pai S, Roy S, Hegde S, Hegde H, Jalalpure S, Peram M. Resolving identification issues of Saraca asoca from its adulterant and commercial samples using phytochemical markers. Pharmacognosy Magazine. 2017;13(50):266. doi:10.4103/pm.pm_417_16
  23. Smitha GR, Thondaiman V. Reproductive biology and breeding system of Saraca asoca (Roxb.) De Wilde: a vulnerable medicinal plant. SpringerPlus. 2016;5(1). doi:10.1186/s40064-016-3709-9
  24. Vasconcelos PCDP, Seito LN, Di Stasi LC, Akiko Hiruma-Lima C, Pellizzon CH. Epicatechin Used in the Treatment of Intestinal Inflammatory Disease: An Analysis by Experimental Models. Evidence-Based Complementary and Alternative Medicine. 2012;2012:1-12. doi:10.1155/2012/508902
  25. Escandón RA, del Campo M, López-Solis R, Obreque-Slier E, Toledo H. Antibacterial effect of kaempferol and (−)-epicatechin on Helicobacter pylori. European Food Research and Technology. 2016;242(9):1495-1502. doi:10.1007/s00217-016-2650-z
  26. Pereyra-Vergara F, Olivares-Corichi IM, Perez-Ruiz AG, Luna-Arias JP, García-Sánchez JR. Apoptosis Induced by (−)-Epicatechin in Human Breast Cancer Cells is Mediated by Reactive Oxygen Species. Molecules. 2020;25(5):1020. doi:10.3390/molecules25051020
  27. Shay J, Elbaz HA, Lee I, Zielske SP, Malek MH, Hüttemann M. Molecular Mechanisms and Therapeutic Effects of (−)-Epicatechin and Other Polyphenols in Cancer, Inflammation, Diabetes, and Neurodegeneration. Oxidative Medicine and Cellular Longevity. 2015;2015:1-13. doi:10.1155/2015/181260